Adarx Pharmaceuticals ADRX
Management team
Background
Ting Feng, Ph.D., has served as a member of our board of directors since October 2025. Dr. Feng has served as Partner at Sirona Capital, a dedicated healthcare venture capital fund, since January 2022. Prior to joining Sirona Capital, Dr. Feng held various investment roles at healthcare venture firms, such as Lilly Asia Ventures (LAV), from December 2018 to January 2022, and SAIF Partners from 2016 to 2018. Dr. Feng currently serves as a member of the board of directors of Synnovation Therapeutics, a precision medicine company, since November 2021. Dr. Feng previously served as a member of the board of members of Shanghai Allist Pharmaceuticals Co., Ltd., a public pharmaceutical company, from November 2019 to March 2022. Dr. Feng also served as a member of the board of directors of ArriVent Biopharma, a public clinical-stage biopharmaceutical company, from June 2021 to January 2022. Dr. Feng received her B.S. in Biotechnology from Wuhan University and her Ph.D. in Immunology from the University of Alabama at Birmingham.
Background
Rui Zhu, Ph.D., is a founding member and has served as our Chief Technology Officer since January 2026, our Senior Vice President, Research from December 2024 to December 2025 and our Vice President, Research and Development since our inception in December 2019 to December 2024. Previously, Dr. Zhu served as a senior scientist at Arrowhead, a public pharmaceutical company, where he successfully co-led five siRNA discovery programs into Phase 1 clinical trials. Dr. Zhu received his B.S. in Chemistry from Nanjing University, his Ph.D. in Organic Chemistry from Tsinghua University and completed his postdoctoral research at Yale University.
Background
Zhen Li, Ph.D., is one of our founding members and has served as a member of our board of directors since our inception in December 2019 and as our President and Chief Executive Officer since January 2020. Dr. Li also was our Chief Financial Officer from January 2020 to September 2022. Dr. Li previously worked at Arrowhead Pharmaceuticals, Inc. (Arrowhead), a public pharmaceutical company, serving as Senior Vice President, Chemistry & Non-Clinical Development. Prior to joining Arrowhead, she served as Director of Chemistry, RNAi therapeutics, Process Chemistry at Merck & Co., Inc. (Merck), a global pharmaceutical company. Prior to her tenure at Merck, she held leadership positions at Schering-Plough Corporation, a pharmaceutical company (acquired by Merck in 2009) and Novartis, and led teams in drug development in small molecule pharmaceuticals. Dr. Li was Director of Chemistry at Merck Research Laboratory and led a team in research and development in the field of siRNA. She led multiple development programs from early to late stage at Schering-Plough. Dr. Li served as the Head of Process and Analytical Research & Development at Novartis Chuangshu. Dr. Li received her B.S. from Peking University and her Ph.D. in Chemistry and Chemical Biology from Harvard University.
Background
Robert Ackles, has served as our Chief People Officer since August 2026. Previously, Mr. Ackles served as Chief People Officer at Acadia Pharmaceuticals Inc., a public biopharmaceutical company from December 2021 to May 2026. Preceding that, at Acadia, Mr. Ackles served as Vice President, People and Performance (CHRO) from December 2016 to December 2021, and as Director, Training and Development from June 2014 to December 2016. Prior to that, Mr. Ackles served in various roles at Santarus, Inc., a biopharmaceutical company, and TAP Pharmaceuticals, Inc., a biopharmaceutical company. Mr. Ackles received his B.A. in Psychology from University of California, Santa Barbara.
Background
Chen Yu, M.D., M.B.A., has served as a member of our board of directors since August 2023. Dr. Yu has served as Founding Managing Partner at TCG Crossover, a biotechnology investment firm, since January 2021. Prior to joining TCG Crossover, Dr. Yu served as Managing Partner at VIVO Capital LLC, an investment firm, from March 2004 to August 2020. From March 2017 to August 2020, Dr. Yu served as Chairman of Surgical Specialties Corporation, a medical device manufacturer, until its merger with Corza Health. Dr. Yu currently serves on the board of directors of various private biotechnology companies. From December 2023 to September 2025, Dr. Yu served as a member of the board of directors of LB Pharmaceuticals Inc, a public pharmaceutical company. From October 2021 to June 2023, Dr. Yu served as a member of the board of directors of Upstream Bio, Inc., a public biotechnology company, and from July 2021 to February 2023, Dr. Yu served as a member of the board of directors of Structure Therapeutics Inc., a public biopharmaceutical company. Dr. Yu received his B.A. in Biology from Harvard University, his M.B.A. from the Stanford University Graduate School of Business and his M.D. from the Stanford University School of Medicine.
Background
Ying Huang, Ph.D., has served as a member of our board of directors since July 2026. Dr. Huang served as Chief Executive Officer of Legend Biotech Corporation, a public biotechnology company, from September 2020 to July 2026 and as Chief Financial Officer from July 2019 until May 2022. Dr. Huang has also served a director of Quanta Therapeutics, Inc., a private biopharmaceutical company, since February 2022, and a director of Third Arc Bio, a private biopharmaceutical company, since September 2024. Previously, Dr. Huang was a Managing Director and Head of Biotech Equity Research at BofA Securities, Inc. from August 2014 to July 2019. Dr. Huang began as a biotechnology analyst in 2007 and previously worked at Wachovia, Credit Suisse, Gleacher and Barclays before joining BofA Securities, Inc. Prior to his Wall Street career, Dr. Huang was a Principal Scientist at Schering-Plough in the Department of Chemical Research focusing on small molecule drug discovery in the therapeutic areas of cardiovascular and central nervous system. Dr. Huang is also the co-author of multiple patents and peer-reviewed publications. Dr. Huang received his M.A., M.Phil and Ph.D in Chemistry from Columbia University. Dr. Huang also studied at Columbia Business School and in the Special Class for the Gifted Young at the University of Science and Technology of China
Background
Ryan Fisk, M.B.A., has served as our Chief Financial Officer and Chief Business Officer since March 2026. Previously, Mr. Fisk served as a Managing Director at Goldman Sachs, an investment bank, from March 2022 to March 2026. From 2016 to March 2022, Mr. Fisk served in various roles at Bank of America Merrill Lynch, an investment bank, including as a Managing Director from 2021 to March 2022 and as a Director and Vice President from 2016 to 2020. Prior to that, Mr. Fisk served in various roles at Credit Suisse, an investment bank, from 2012 to 2016, including as a Vice President and as an Associate. Mr. Fisk received his B.A. in Economics and Political Science from UCLA and his M.B.A. from Columbia Business School.
Background
Judith J. Li, M.B.A., has served as a member of our board of directors since September 2021. Ms. Li has served as Partner at LAV, a biomedical venture capital firm, since November 2013. Ms. Li has served as a member of the board of directors of multiple LAV portfolio companies, including Tmunity Therapeutics Incorporated (acquired by Kite Pharma, Inc., a public biotechnology company, in 2023), a biotechnology company, since January 2016, Scineuro Pharmaceuticals, a private pharmaceutical company, since December 2020, and Fortis Therapeutics, a biotechnology company, since June 2016. Ms. Li previously served as a member of the board of directors at Gritstone Oncology, Inc., a public biotechnology company, from September 2017 to January 2022. Ms. Li has also previously served as a member of the board of directors of Inhibrx, Inc., a public biotechnology company, from May 2018 to June 2020, and Nextcure, Inc., a public biopharmaceutical company, from December 2015 to September 2020. Ms. Li received her B.A. in Biology from Harvard University and her M.B.A. from Harvard Business School.
Background
A. Robert MacLeod, Ph.D., has served as our Chief Scientific Officer since January 2023. From September 2021 to December 2022, Dr. MacLeod served as Chief Scientific Officer at Flamingo Therapeutics, Inc., a biotechnology company. Prior to that, Dr. MacLeod served in various roles at Ionis Pharmaceuticals, Inc., a public biotechnology company, from October 2008 to September 2021, including Vice President and Franchise Head of Oncology, Vice President of Oncology and Exploratory Discovery and Executive Director of Discovery Biology. In his prior positions, Dr. MacLeod led the strategic and scientific efforts of several multidisciplinary drug discovery teams leading to the discovery and clinical development of novel investigational therapeutics and numerous scientific publications and patents. Dr. MacLeod received his B.S. in Chemistry and Biochemistry from Concordia University Montreal, Quebec, Canada and his Ph.D. in Cancer Epigenetics from McGill University.
Background
Ricky Sun, Ph.D., M.B.A., has served as a member of our board of directors since August 2023. He joined Bain Capital Life Sciences, LP (Bain Capital) in August 2016 and has been a Partner since January 2021. Prior to joining Bain Capital, he was a Director of Corporate Development and Strategy at Biogen Inc., a publicly-held biotechnology company, from 2013 to 2016. Prior to Biogen, Dr. Sun served as a Vice President at BlackRock, Inc., (BlackRock) as a member of the Fundamental Equity division of BlackRock's Alpha Strategies Group and senior analyst for BlackRock's Fundamental Large Cap Growth equity team, covering the health care sector. Prior to that, he was a senior healthcare analyst at Citadel and Alyeska Investment Group and worked as a pharmaceuticals equity research analyst at Lehman Brothers and Morgan Stanley. Dr. Sun began his career as a senior scientist at Ironwood Pharmaceuticals, Inc., a public pharmaceutical company, where he was involved in the discovery and development of the drug Linzess for irritable bowel syndrome. Dr. Sun previously served as a member of the board of directors of Annexon, Inc., a public biotechnology company, from December 2018 to February 2022, Arcutis Biotherapeutics, Inc., a public biotechnology company, from August 2018 to September 2021, and Savara, Inc., a public biotechnology company, from December 2019 to April 2024. Dr. Sun received his Ph.D. in Chemistry and Chemical Biology from Harvard University and was an NIH post-doctoral fellow in Biological Chemistry & Molecular Pharmacology at Harvard Medical School. He also received his M.B.A. from New York University Stern School of Business, where he was a Mildred Elperin Scholar. He graduated summa cum laude from Berea College with a B.A. in Chemistry.
Background
Mary Tagliaferri, M.D., has served as a member of our board of directors since November 2025. Dr. Tagliaferri currently serves as the Chief Medical Officer and Senior Vice President of Nektar Therapeutics, Inc., a public biopharmaceutical company, since September 2025, where she also served in the same capacity from 2017 to February 2025 and in various roles since January 2015. Dr. Tagliaferri also has served on the board of directors of Iambic Therapeutics, a private AI-driven biotechnology company, since August 2024, and on the board of directors of Y-mAbs Therapeutics, Inc., a public commercial-stage biopharmaceutical company, from February 2024 to August 2025. Prior to that, Dr. Tagliaferri served on the board of directors of RayzeBio, Inc., a public biotechnology company, from September 2021 until its acquisition by Bristol-Myers Squibb in February 2024, and on the board of directors of Enzo Biochem, Inc., a public biotechnology company, from November 2020 to August 2024. Dr. Tagliaferri received her B.S. in Agricultural Economics and Business Management from Cornell University and her M.D. from the University of California, San Francisco.
Background
Carl L. Gordon, Ph.D., CFA, has served as a member of our board of directors since January 2020. Dr. Gordon is a Managing Partner at OrbiMed Advisors LLC, an investment firm. Dr. Gordon currently serves on the boards of directors of Compass Therapeutics Inc. and Lomond Therapeutics Holdings, Inc., as well as several private companies. Dr. Gordon previously served on the boards of directors of several publicly-traded companies, including Adicet Bio, Inc. from August 2015 to April 2025, ArriVent Biopharma, Inc. from December 2022 to June 2025, Gemini Therapeutics, Inc. (which merged with Disc Medicine, Inc.) from April 2016 to December 2022, Keros Therapeutics, Inc. from March 2020 to March 2026, Kinnate Biopharma, Inc. from December 2019 to April 2024, MBX Biosciences, Inc. from July 2020 to June 2025, ORIC Pharmaceuticals, Inc. from November 2015 to November 2021, Terns Pharmaceuticals, Inc. from October 2018 to February 2025, and Theseus Pharmaceuticals, Inc. from June 2018 to February 2024. Dr. Gordon received his B.A. in Chemistry from Harvard College, his Ph.D. in Molecular Biology from the Massachusetts Institute of Technology, and was a Fellow at The Rockefeller University.
Background
Erez Chimovits, M.B.A., has served as a member of our board of directors since May 2020. Mr. Chimovits is a Partner at OrbiMed, an investment firm, where he has served in various roles of increasing responsibility since November 2010. Mr. Chimovits currently serves on the boards of directors of Upstream Bio, Inc. and several private companies. Mr. Chimovits previously served on the boards of directors of several public biotechnology companies, including Adicet Bio, Inc. from January 2016 until March 2021, BiomX, Inc. from December 2015 until October 2020, LogicBio Therapeutics, Inc. from January 2016 until December 2020, and Novus Therapeutics, Inc. (now Eledon Pharmaceuticals, Inc.) from June 2017 until September 2020. Prior to joining OrbiMed, Mr. Chimovits served as Chief Executive Officer of NasVax Ltd. (now SciSparc Ltd.), a public biotechnology company, from January 2007 to November 2010. Previously, Mr. Chimovits served as President of Compugen USA Inc., a subsidiary of Compugen Ltd., a public biotechnology company, from January 2001 to January 2007, and as Executive Vice President, Commercial Operations from December 1999 to January 2007. Mr. Chimovits earned his B.S., M.S. in Microbiology, and his M.B.A. from Tel Aviv University.
Background
Simeon George, M.D., M.B.A., has served as a member of our board of directors since July 2021. Dr. George has served as Chief Executive Officer and Managing Partner of SR One Capital Management, LP, a transatlantic healthcare investment firm, since September 2020. Dr. George previously served in various roles at S.R. One, Limited (now called GSK Equity Investments, Limited), an indirect, wholly-owned subsidiary of GlaxoSmithKline plc, a biotechnology venture capital firm, from 2007 to September 2020, most recently serving as Chief Executive Officer from January 2018 to September 2020. Dr. George has served as a member of the board of directors of Nkarta, Inc., a public biotechnology company, since February 2020 and previously served on such board of directors from February 2015 to September 2017, CRISPR Therapeutics AG, a public biotechnology company, since March 2015 and Design Therapeutics, Inc., a public biotechnology company, since February 2020. Dr. George previously served as a member of the board of directors of Principia Biopharma Inc. (acquired by Sanofi in 2020), a biopharmaceutical company, from February 2011 to September 2020, Progyny, Inc., a health benefits management company, from May 2012 to October 2019, and Turning Point Therapeutics, Inc. (acquired by Bristol Myers Squibb in 2022), a public biopharmaceutical company, from May 2017 to August 2022. Dr. George received his B.A. in Neuroscience from Johns Hopkins University, his M.D. from the University of Pennsylvania School of Medicine and his M.B.A. (Mayer Scholar) from the Wharton School of the University of Pennsylvania.
From SEC filings, via Futu. Compensation is total reported pay for the most recent fiscal year on file, not base salary alone.
No comments yet — be the first to weigh in on ADRX.
Sign in to join the discussion.